Presidential Reception celebrating Female Entrepreneurship, Innovation, Creativity & Sustainable

DUBLIN, IRELAND – May 10, 2018 – Founder & Chief Scientific Officer of ATXA Therapeutics, Prof. Therese Kinsella, attended a reception...

ATXA Therapeutics to Attend the 2018 Medtech Strategist Innovation Summit

DUBLIN, IRELAND – April 3, 2018 – ATXA Therapeutics Limited Founder and Chief Scientific Officer, Prof. Therese Kinsella, PhD, MRIA, will...

FDA Grants Orphan Drug Designation to ATXA’s NTP42 for the Treatment of PAH

DUBLIN, IRELAND – March 8, 2018 – ATXA Therapeutics Limited, an early-stage Irish biopharmaceutical company focused on clinical...

ATXA Therapeutics receives EMA Orphan Drug Designation for NTP42 for the treatment of Pulmonary Arte

DUBLIN, IRELAND – February 23, 2018 – ATXA Therapeutics Limited, an early-stage Irish biopharmaceutical company focused on clinical...

ATXA Therapeutics to Present at the 2018 Biotech and Money / Medtech and Money World Congress Showca

DUBLIN, IRELAND – February 2, 2018 – ATXA Therapeutics Limited, an early-stage Irish biopharmaceutical company focused on clinical...

COMPANY UPDATES